SCOTTSDALE, Ariz., Nov. 29, 2021 (GLOBE NEWSWIRE) Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), expanded the company’s board of
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
Fortress Biotech, Inc.May 16, 2021 GMT
Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021
On track to report top-line results from the registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma by year-end 2021
Ended first quarter 2021 with $291.5 million in consolidated cash, cash equivalents and restricted cash
NEW YORK, May 16, 2021 (GLOBE NEWSWIRE) Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced financial results and recent corporate highlights for the first quarter ended March 31,
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad .
Fortress Biotech, Inc.May 10, 2021 GMT
Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney disease and heart failure
Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia
Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company, today announced that it has entered into an exclusive licensing agreement with Fuji Yakuhin Co. Ltd. (“Fuji”) to develop Dot
Aprilâs Biggest Closing Takes Place at 15 Central Park West
A duplex penthouse owned by Lindsay A. Rosenwald, a bio pharmaceuticals investor, sold for nearly $46.7 million after nearly three years on the market.
The largest sale in New York City in April was a penthouse at 15 Central Park West, with a wraparound terrace overlooking the park.Credit.Benjamin Norman for The New York Times
May 7, 2021
A spacious duplex at 15 Central Park West with a wraparound terrace directly overlooking the park topped the list of home sales in New York City during the month of April.
The penthouse, on the 18th and 19th floors in the coveted âhouseâ portion of the twin-towered limestone complex, closed at nearly $46.7 million. It had been on the market, though, since late summer 2019 for as much as $65 million.
Our six dermatology products are marketed by our partner company, Journey Medical Corporation (“Journey”).
Our products generated net revenues of $44.5 million for full-year 2020, compared to full-year 2019 net revenues of $34.9 million, representing growth of 28%. Our products generated $13.7 million in revenues in the fourth quarter of 2020, compared to $11.1 million in the fourth quarter of 2019, representing growth of 23%. While we generated revenue growth year-over-year in 2020, sales of our products were impacted by the COVID-19 pandemic, which caused a temporary supply shortage and impacted the ability of our sales force to make in person calls, due to states slowly re-opening.
We in-licensed and recently launched our sixth prescription dermatology product.